First Trust Advisors
PRVL

First Trust Advisors’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

First Trust Advisors’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,571
Closed -$382K – 2502
2020
Q4 		$382K Sell
16,571
-733
-4% -$9.29K ﹤0.01% 2177
2020
Q3 		$176K Buy
+17,304
New +$232K ﹤0.01% 2247

First Trust Advisors's PRVL Position: Q1 2021 in Review

First Trust Advisors sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 16,571 shares — an estimated $382K sold.

First Trust Advisors first reported a position in PRVL in Q3 2020 and held it in 2 quarters. The position peaked at $382K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • First Trust Advisors reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • First Trust Advisors sold 16,571 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $382K.
  • First Trust Advisors first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • First Trust Advisors's Prevail Therapeutics Inc. Common Stock position peaked at $382K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on First Trust Advisors's 13F filing for Q1 2021, filed 14 May 2021.